These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25252033)

  • 1. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.
    Kan H; Yamagishi S; Ojima A; Fukami K; Ueda S; Takeuchi M; Hyogo H; Aikata H; Chayama K
    J Clin Lab Anal; 2015 Nov; 29(6):480-4. PubMed ID: 25252033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
    J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection.
    Nishio T; Hatano E; Sakurai T; Taura K; Okuno M; Kasai Y; Seo S; Yasuchika K; Mori A; Kaido T; Uemoto S
    Ann Surg Oncol; 2015 Jul; 22(7):2226-34. PubMed ID: 25395147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Features and Outcomes of Non-B, Non-C Hepatocellular Carcinoma After Hepatectomy.
    Takeishi K; Maeda T; Shirabe K; Tsujita E; Yamashita Y; Harimoto N; Itoh S; Ikegami T; Yoshizumi T; Maehara Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1116-24. PubMed ID: 26159442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Takino J; Nagamine K; Hori T; Sakasai-Sakai A; Takeuchi M
    World J Hepatol; 2015 Oct; 7(23):2459-69. PubMed ID: 26483867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
    Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
    Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
    Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study.
    Kim SK; Marusawa H; Eso Y; Nishikawa H; Ueda Y; Kita R; Kimura T; Chiba T; Osaki Y; Kudo M
    Digestion; 2011; 84 Suppl 1():43-9. PubMed ID: 22156485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
    Nagaoki Y; Hyogo H; Ando Y; Kosaka Y; Uchikawa S; Nishida Y; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Okamoto W; Kawaoka T; Tsuge M; Hiramatsu A; Miki D; Imamura M; Takahashi S; Chayama K; Aikata H
    BMC Gastroenterol; 2021 Jul; 21(1):306. PubMed ID: 34332532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.
    Lee SB; Kim KM; An J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS
    Liver Int; 2016 Sep; 36(9):1351-61. PubMed ID: 26913702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Aby E; Phan J; Truong E; Grotts J; Saab S
    J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of non-B, non-C hepatocellular carcinoma: The impact of patient sex on disease-free survival - A retrospective cohort study.
    Hashimoto M; Tashiro H; Kobayashi T; Kuroda S; Hamaoka M; Ohdan H
    Int J Surg; 2017 Mar; 39():206-213. PubMed ID: 28159713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
    Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
    PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
    Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
    Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
    Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.
    Omichi K; Shindoh J; Yamamoto S; Matsuyama Y; Akamatsu N; Arita J; Kaneko J; Sakamoto Y; Hasegawa K; Kokudo N
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1034-40. PubMed ID: 26350363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
    Tanaka S; Miyanishi K; Kobune M; Kawano Y; Hoki T; Kubo T; Hayashi T; Sato T; Sato Y; Takimoto R; Kato J
    J Gastroenterol; 2013 Nov; 48(11):1249-58. PubMed ID: 23329365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.